The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyond

Hepatology

Volumn 43, Issue 3, 2006, Pages 385-394

  Moreau, Richard ^a   Lebrec, Didier ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; CREATININE; DOPAMINE; FUROSEMIDE; MIDODRINE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PLACEBO; TERLIPRESSIN; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR;

BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; GRAM NEGATIVE BACTERIUM; HEPATORENAL SYNDROME; HUMAN; HYPOTENSION; ISCHEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPLANCHNIC BLOOD FLOW; STATISTICAL SIGNIFICANCE; SURVIVAL; THORAX PAIN; TREATMENT OUTCOME; VASOCONSTRICTION; VASODILATATION;

ADRENERGIC ALPHA-AGONISTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LYSINE VASOPRESSIN; PARACENTESIS; SHOCK, SEPTIC; SPLANCHNIC CIRCULATION; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 33645241832     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21094     Document Type: Review

References (50)

1. Lebrec D. Pharmacological treatment of portal hypertension: present and future. J Hepatol 1998;28:896-907.
2. de Franchis R. Evolving consensus in portal hypertension: report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-176.
3. Uriz J, Ginès P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-48.
4. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001;64:15-19.
5. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni J-P, Ichaï P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-930.
6. Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, et al. Effect of terlipressin (Glypressine) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-158.
7. Ortega R, Ginès P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepato-renal syndrome: results of a prospective, nonrandomized study. HEPATOLOGY 2002;36:941-948.
8. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-156.
9. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of mido-drine and octreotide. HEPATOLOGY 1999;29:1690-1697.
10. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. HEPATOLOGY 2004;40:55-64.
11. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study. HEPATOLOGY 2002;36:374-380.
12. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363-1368.
13. Moreau R, Asselah T, Condat B, De Kerguenec C, Pessione F, Bernard B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002;50:90-94.
14. Moreau R, Barrière E, Tazi KA, Lardeux B, Dargère D, Urbanowicz W, et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. HEPATOLOGY 2002;36:1070-1078.
15. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. HEPATOLOGY 1996;23:164-176.
16. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. HEPATOLOGY 2003;37:233-243.
17. Ginès A, Escorsell A, Ginès P, Salo J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
18. Moore K. The hepatorenal syndrome. Clin Sci 1997;92:433-443.
19. Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. HEPATOLOGY 2001;34:1242-1251.
20. Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 2002;17:739-747.
21. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003;362:1819-1827.
22. Ginès P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-1654.
23. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. HEPATOLOGY 2005;41:1282-1289.
24. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodès J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988;8:1151-1157.
25. Fernandez-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriguez-Eire JL, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989;97:1304-1312.
26. Henriksen JH. Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis. J Hepatol 1995;23:25-30.
27. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. HEPATOLOGY 2005;42:439-447.
28. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
29. Lenz K, Hortnagel H, Druml W, Reither H, Schmid R, Schneeweiss B, et al. Ornipressin in the treatment of functional renal failure in decompensated cirrhosis: effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991;101:1060-1067.
30. Gadano A, Moreau R, Vachiery F, Soupison T, Yang S, Cailmail S, et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 1997;26:1229-1234.
31. Moller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000;20:51-59.
32. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the two-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-570.
33. Guevara M, Ginès P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. HEPATOLOGY 1998;27:35-41.
34. G̈lberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamin. HEPATOLOGY 1999;30:870-875.
35. 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982;82:97-105.
36. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 1995;22:370-376.
37. Medel J, Boccara G, Van de Steen E, Bertrand M, Godet G, Coriat P. Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia? Anesth Analg 2001;93:53-55.
38. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. HEPATOLOGY 2003;38:238-243.
39. Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, et al. Clinical course, predictive factors and prognosis of hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002;17:882-888.
40. Ginès P, Torre A, Terra C, Guevara M. Review article: pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther 2004;20(Suppl 3):57-62.
41. Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a case-control study. J Hepatol 2004;40:140-146.
42. Moreau R. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation. J Hepatol 2004;40:159-161.
43. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, et al. Acute effects of oral administration of midodrine, an α-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. HEPATOLOGY 1998;28:937-943.
44. Benditt DG, Fahy GJ, Lurie KG, Sakaguchi S, Fabian W, Samniah N. Pharmacotherapy of neurally mediated syncope. Circulation 1999;100:1242-1248.
45. Moore KP, Wong F, Ginès P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. HEPATOLOGY 2003;38:258-266.
46. Ginès A, Fernandez-Esparrach G, Monescillo A, Vila C, Doménech E, Abecasis R, et al. Randomized trial comparing albumin, Dextran. 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-1010.
47. Ruiz-Del-Arbol L, Monescillo A, Jiménez W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579-586.
48. Cohen J. Immunopathogenesis of sepsis. Nature 2002;420:885-891.
49. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med;345:588-895.
50. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005;54:718-725.